#bestatin | Explore Tumblr posts and blogs

abbkine · 5 years ago

Text

New Post has been published on Abbkine - Antibodies, proteins, biochemicals, assay kits for life science research

Western Blot Product Portfolio- Sample Preparation

Overview of western blot (WB):

Western Blot is an experimental method commonly used in molecular biology, biochemistry and immunogenetics. The basic principle is to color the cell or biological tissue samples treated by gel electrophoresis through specific antibodies. Information on the expression of specific proteins in the analyzed cells or tissues is obtained by analyzing the staining position and staining depth.

Sample preparation:

Good protein is half the success of WB. We need to lyse cells and tissues to extract the target protein. Once cracking occurs, hydrolysis, dephosphorylation and denaturation begin. If appropriate protease or phosphatase inhibitor is added to the cracking solution, these reactions will be greatly slowed down and the chance of extracting good protein will be increased.

It takes time and effort to prepare lysis solution by oneself, and the whole experiment may be wasted due to improper preparation. Why not try the protein extraction kit that Abbkine has packed for you? The kit is equipped with optimized lysis components. You only need to carry out the experiment according to the experimental steps.

Abbkine sample preparation product recommendation:

Product name #Cat Szie Price ($) ExKine™ Nuclear and Cytoplasmic Protein Extraction Kit KTP3001 50/200T 90/220 ExKine™ Nuclear Protein Extraction Kit KTP3002 50/200T 80/200 ExKine™ Cytoplasmic Protein Extraction Kit KTP3003 50/200T 80/200 ExKine™ Total Membrane Protein Extraction Kit KTP3004 50/200T 80/200 ExKine™ Membrane and Cytoplasmic Protein Extraction Kit KTP3005 50/200T 90/220 ExKine™ Total Protein Extraction Kit KTP3006 50/200T 80/200 Protease Inhibitor Cocktail (100X) BMP1001 1ml/1mlx5 40/120

The basic process of protein extraction

Characteristics and Advantages of Abbkine Protein Extraction Kit:

High purity and no pollution-the extracted protein has high purity and maintains natural activity, reducing cross contamination;

Strong timeliness-non-denatured active protein can be purified within two hours;

Compatible application-the extracted protein can be directly used in subsequent proteomics applications;

Follow-up worry-free-kits own a special protease inhibitor package, anti-degradation, anti-useless;

High cost performance.

Characteristics and Advantages of Abbkine Protease Inhibitor Cocktail (100X):

Abbkine Protease Inhibitor Cocktail is an universal protease inhibitor cocktail contains individual components, including AEBSF, Aprotinin, Bestatin, E-64, Leupeptin and Pepstatin A with a broad specificity for cysteine, serine, acid proteases, and aminopeptidases. This protease inhibitor cocktail has been optimized and tested for mammalian cells and tissue extracts.

You deserve to have good sample preparation products!

#protease inhibitor #protein extraction #WB #Western Blot

0 notes

marketexclusive · 8 years ago

Text

What To Look Out For In The Latest Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Trial

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) just announced first dosing in its phase II LIBERTY trial, and markets seem to have turned a blind eye to the development. The company is down a percentage point ahead of Tuesday’s open in the US, trading for a market cap of a little over $134 million.

There’s every chance markets are waiting on data from the trial before committing to a bias. With this in mind, and ahead of any interim updates, let’s take a look at the drug in question and try and figure out what impact it might have on Eiger going forward.

The drug is called ubenimex, or bestatin, and it’s part of a family of drugs called leukotriene inhibitors. In the phase II Eiger just kicked off, it has a target indication of pulmonary arterial hypertension, but it’s already approved in Japan as an adjunct to chemotherapy. It’s administered alongside whatever chemotherapy drug a patient is receiving, and designed to improve the efficacy of the latter. So why go after a PAH indication in the US? Well, a specific type of leukotriene, LTB4, is thought to be linked to inflammation, and the inflammation is the root cause of PAH. LTB4 is produced by what’s called leukotriene A4 hydrolase, and ubenimex inhibits leukotriene A4 hydrolase. Through this inhibition, Eiger is hoping it can delay or stop the production of LTB4, the body’s inflammatory response to this production, and in turn, treat PAH.

The trial that just kicked off is a multi-center, randomized, double-blind, placebo-controlled trial, with all patients PAH sufferers. Eiger is aiming to bring 45 patients into the study, of which two out of three will receive ubenimex, while the remaining third will receive placebo. It’s a twenty-four-week trial, with a twenty-four-week extension period. The primary endpoint is a change from baseline in what’s called pulmonary vascular resistance (PVR). PVR is a calculation used by physicians to diagnose and monitor PAH, and its based on a combination of three factors – mean pulmonary artery pressure, left atrial pressure and pulmonary flow. The results are measured in a unit called dynes-sec-cm-5, and in the data release we are looking for a reduction from the baseline number. Normal PVR is circa 67, with a +-30 dynes-sec-cm-5, so ideally we’re looking for patients that kicked off the trial with a high PVR, and registered as close to 67 as possible come the 24-week measurement point (and beyond that, maintained this reduction to the second 24 week extension measurement point).

What’s the market like for this sort of treatment? Well, the PAH therapeutic space is worth around $3.5 billion right now, and analysts expect this to run at a CAGR of circa 3% between now and 2024, giving the condition a forward market size of $4.75 billion. Current treatments don’t target the inflammation associated with the condition, so if Eiger can demonstrate efficacy in reducing or removing this inflammation, it would have a good chance at rapid double digit market penetration.

So what are we looking for going forward? Well, the trial in question is set to wrap up in September next year, but there should be plenty of opportunities to garner insight into the status of the trial between now and then. It’s reasonable to assume that once the 45 patient target has been reached we’ll see an update, and this might be a minor upside catalyst, but the real catalyst will be on interim once the 45 patients have completed their first round of 24 weeks’ worth of dosing. At that point, Eiger will have a pretty solid data set, and should serve up some interim figures. Any reduction in PVR from baseline would be good, with the higher the reduction the higher the impact in terms of upside we are likely to see. There are a few secondaries in play, and of these, the headline is probably the six-minute walk test, so keep an eye out for an improvement from baseline on this one as a kicker to the primary efficacy endpoint.

All said, it’s going to be an interesting six months for the company. If it can present us with some interim that suggests efficacy, speculative capital will likely flow in ahead of topline. One to keep an eye on. Cautiously, but well worth a look.

What To Look Out For In The Latest Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Trial was originally published on Market Exclusive

#Bestatin #biotech #EIGR #FDA #pulmonary arterial hypertension #stocks

0 notes